England's NHS offers new blood cancer therapy

upi.com

England's NHS is the first health system globally to offer a new "trojan horse" blood cancer therapy, significantly extending the time patients live without cancer progression. The new treatment, belantamab mafodotin, targets multiple myeloma, a type of bone marrow cancer. It works by delivering a lethal molecule directly into cancer cells, destroying them from within, and has shown promise in clinical trials. This innovative therapy, developed in the UK, offers new hope to over 6,000 annual multiple myeloma patients in Britain, potentially tripling the time before cancer progression compared to existing treatments.


With a significance score of 4.8, this news ranks in the top 1.9% of today's 29634 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


England's NHS offers new blood cancer therapy | News Minimalist